T here is a need to limit exposure to red blood cell transfusion (RBCT) in obstetric patients not only because of the potential of maternal adverse events but because alloimmunization secondary to RBCT may also potentially affect fetal or neonatal outcomes if an alloantibody predisposes to hemolytic disease of the fetus and newborn. 1, 2 Transfusion has been shown to be one of the main causes of maternal alloimmunization to K antigen 1, 2 and to other Rh non-D antigens. 2 The most compelling reason to transfuse an obstetric patient is for hemorrhage. Aside from hemorrhage, the American College of Obstetrics and Gynecology suggests that RBCT should be considered for fetal indications, that is, if there are signs of fetal hypoxygenation 3 as maternal anemia potentially affects fetal oxygenation. 4 Yet, despite this, it has been suggested that obstetric patients are unnecessarily exposed to blood products because of the lack of clear indications for blood transfusion. [5] [6] [7] [8] As there are limited data on the risk factors associated with RBCT, that is, what obstetric subpopulations are being transfused, as well as trends for RBCT for these patients, ascertaining this information can aid in identifying patient groups who may benefit from alternatives to RBCT ultimately reducing maternal and fetal risks of exposure to RBCT. 9 Indeed, identifying and reporting trends in RBCT also assists in prioritizing research initiatives and predicting demand. 10 Accordingly, the objective of this study was to assess risk factors and trends of RBCT among obstetric patients delivering at a tertiary hospital center according to mode of delivery.
MATERIALS AND METHODS

Study design
We conducted a retrospective cohort study using administrative data from an academic hospital in Ottawa, Canada, to evaluate obstetric RBCT patterns and, further, to identify factors associated with RBCT in obstetric patients at delivery. This study was approved by the Ottawa Health Science Network Research Ethics Board.
Data source
The 
Risk factors and outcomes
As hemorrhage is a common indication for RBCT, known and suspected risk factors for postpartum hemorrhage (PPH), such as abnormal uterine contractility, invasive placentation, and perineal trauma were assessed. [11] [12] [13] [14] The following were also a priori considered as risk factors: maternal age, development of pregnancy complications (e.g., hypertensive disorders of pregnancy, antepartum hemorrhage, polyhydramnios), hematologic disorders (e.g., hemoglobinopathy, thrombocytopenia), [15] [16] [17] [18] ICD-10 classification codes used to identify patients from OHDW are provided in Appendix S2 (available as supporting information in the online version of this paper). ICD-9 codes associated with obstetric discharge diagnoses have been previously validated. 19 Those ICD-9 codes with a positive predictive value of more than 70% were used, but revised to reflect ICD-10 classification.
Statistical analysis
Means, medians, and measures of standard dispersion (standard deviation [SD] and interquartile range [IQR]) were used to describe the populations. Comparisons across mode of delivery (SVD, IVD, C/S) were performed using the likelihood ratio chi-square test. Data on units of RBCT were compared across all three modes of delivery using the Mann-Whitney nonparametric test.
To investigate the potential association between perinatal risk factors and the risk of an RBCT at delivery, we conducted a longitudinal analysis using generalized estimating equations to test for the association of each RBCT received at delivery over multiple pregnancies. Exposures were clustered at the patient level rather than at the hospitalization level to account for patients having more than one delivery over the study period. Three models were developed, one for each mode of delivery. All risk factors were included in the initial model, regardless of the univariate statistical significance.
The interaction between number of previous deliveries (zero, one, two or more previous deliveries) and each risk factor was investigated across all deliveries to assess whether a given risk factor had the same risk over repeated pregnancies. Interactions between induction of labor (dichotomized as "no induction" vs. "attempted induction") and each exposure were also tested. Interaction models are provided in Appendix S3 (available as supporting information in the online version of this paper). Only interactions significant at p values of less than 0.05 were included in the adjusted model. Risk factors or interactions with a Wald test p value of more than 0.1 were considered nonpredictive of RBCT in the final model. Subsequently, the least significant risk factor or interaction was excluded from the model in a backward stepwise fashion, and the model was recalibrated. This process was repeated until all factors included in the final model had a Wald test p value of not more than 0.1. Risk factors were defined as those with a p value between 0.05 and 0.1, and variables with a p value of less than 0.05 were considered to be associated with RBCT. Risk factors that were excluded from the models varied by mode of delivery. The PLT count, INR, obesity or excessive weight gain, uterine rupture, and neonatal weight were excluded for SVD; the Hb level, the PLT count, aPTT, INR, hemoglobinopathies, obesity or excessive weight gain, placental abruption, placenta previa, infection from uterine cavity, uterine rupture, and neonatal weight for IVD; and the PLT count and neonatal weight for C/S.
RBCT trends over time at delivery were assessed using regression models for each mode of delivery. Variations in obstetric deliveries receiving RBCT and the number of units of RBCT administered per delivery admission were assessed.
Complete case analysis was used for the model and all analyses were performed using computer software (SAS, Version 9.3, SAS Institute, Inc.). All tests of statistical inference reflected a two-tailed alpha of 0.05.
RESULTS
Patient characteristics
Of the 45,213 deliveries captured during the study period, 14,277 (31.6%) were C/Ss, 26,994 (59.7%) were SVDs, and 3942 (8.7%) were IVDs. The median maternal age across all patients was 31 years (IQR, 28-35 years) and the median duration of hospitalization was 3 days (IQR, 2-3 days). Patients undergoing C/S had higher rates of RBCT, 2.3% versus 0.7% and 1.5% for SVDs and IVDs, respectively (p < 0.001).
Of those women delivering by C/S, 9733 (68.2%) were elective procedures and 4544 (31.8%) were emergent.
Women undergoing emergent C/S had a higher rate of RBCT (4.0%) compared to women delivering by elective C/S (1.5%) and received more RBC units (median [ A Hb level was not available for approximately 50% to 60% of all women who underwent vaginal deliveries compared to less than 1% for women who delivered by C/S. Emergent deliveries were more likely not to have a Hb level before the RBCT compared to elective procedures (9.3% vs. 2.7%, p 5 0.016). The rate of PPH was highest among women with IVDs, 10.1%. Patient characteristics by mode of delivery are summarized in Table 1 .
Patterns in RBCT over time
A total of 1729 RBC units were transfused over the study period; 499 units were given to patients who delivered by SVD, 170 to those who delivered by IVD, and 1060 to those who delivered by C/S. A total of 571 patients received RBCT; 0.7% who delivered by SVD, 1.5% who delivered by IVD, and 2.3% of women who delivered by C/S received RBCT. After adjustment for all variables associated with RBCT, log-linear regression analysis identified that the relative risk (RR) of RBCT increased 57% over the study interval, from 2007 to 2013 for patients undergoing C/S (p 5 0.0054). There was no significant change in RR of RBCT for other modes of delivery (Table 2) . Figure 1 demonstrates the mean number of RBC units administered per admission over time according to mode of delivery. A mean of 3.03 6 2.80 RBC units were transfused per patient transfused over the study period. Overall, 11.4, 57.4, 9.8, 8.1, and 13.3% of patients transfused received 1, 2, 3, 4, or 5 or more RBC units.
No significant difference in volume of RBC administration by mode of delivery (SVD, 2.73 6 2.05; IVD, 2.88 6 2.36; C/S, 3.22 6 3.20; p 5 0.146) was observed. There was no change in the mean number of RBC units over the study interval (p 5 0.091).
Adjusted RRs of RBCT by mode of delivery
We excluded 38 deliveries (30 SVD, one IVD, and seven C/ S) due to either missing gestational age or number of previous deliveries. Exclusion of these deliveries was associated with a loss of 0.11, 0.03, and 0.05% of data for SVD, IVD, and C/S, respectively.
For women undergoing SVD, PPH, need for an intensive care unit (ICU) visit, invasive placentation, and retained placental products were associated with RBCT. In addition, the adjusted RR of receiving RBCT was considerably higher for patients having Hb levels of less than 100 g/L compared to patients with Hb levels of 100 g/L or more. Final adjusted RRs associated with RBCT for SVD are summarized in Table 3 .
The RRs of RBCT for patients undergoing IVDs were highest among those with PPH (RR, 19.98; 95% CI, 10.76-37.11). Retained placental products and delivery of multiples were also significantly associated with RBCT as was requiring an ICU visit during hospital admission (Table 3) .
Several other factors were associated with increased likelihood of receiving RBCT for women undergoing C/S (Table 3) . Low Hb levels were associated with higher frequency of RBCT: for 0 to 70 g/L, RR was 34.64 (95% CI, 24.02-49.95), and for 70 to 80 g/L, RR was 7.78 (95% CI, 5.21-11.60). Women with unmeasured Hb levels also exhibited a stronger likelihood of RBCT, with an RR of 12.94 (95% CI, 7.39-22.66). An unavailable aPTT and INR as well as high INRs were associated with RBCT. Specific to C/Ss were maternal history of cardiovascular disease, maternal obesity or excessive weight gain, and the presence of a hemoglobinopathy. PPH and deliveries requiring an ICU visit were common risk factors of RBCT across all modes of delivery. A greater proportion of patients with PPH required RBCT compared to those who did not hemorrhage after delivery and received a greater number of RBC units (Table 4) .
DISCUSSION
This study of 45,213 deliveries categorized according to mode of delivery demonstrated that RBCTs were higher for C/Ss than for SVDs and that there was a significant increase in the risk of RBCT for women undergoing C/S over the 7-year interval. Women delivering by SVD or by C/S were more likely to receive RBCT if they had low or unmeasured Hb levels. An association between unavailable Hb levels and risk of RBCT, in particular, unavailable Hb levels among women undergoing C/S, may have been secondary to the need for emergent C/S. Emergent C/S constituted 31.8% of all C/S, more patients having emergent C/S had unavailable Hb levels and received RBCs than those who underwent elective C/S procedures.
Only three risk factors for RBCT were identified across all three modes of delivery, PPH, earlier gestational age among women for whom induction was attempted, and deliveries requiring an ICU visit during hospital admission suggesting that separate risk stratification scores (for each mode of delivery) need to be developed. Further supporting the need for separate risk stratification scores are the associations specific to each mode of delivery such as invasive placentation for SVD; delivery of multiples for IVD; and maternal history of cardiovascular disease, maternal obesity or excessive weight gain, and the presence of a hemoglobinopathy for women undergoing C/S.
Earlier gestational age at induction was the only potentially modifiable antenatal risk factor for all three modes of delivery. The other potentially modifiable risk factors for RBCT that differed according to mode of delivery that may be targeted to reduce exposure to RBCT include a low maternal Hb concentration. Low maternal Hb levels may be targeted by early antenatal treatment with iron supplementation to increase overall Hb levels 20 as the most common cause of a low Hb levels in pregnancy is iron deficiency. 21 Iron supplements also decrease the risk of maternal anemia at delivery. 3 The measurement of Hb levels may also reduce the exposure to RBCT as the lack of availability of a Hb level resulted in RBCT. The measurement of Hb level before delivery is not routine and potentially unanticipated hemorrhage with the inability to obtain a Hb level may lead to RBCT. All women should have a Hb level measured when first assessed and at 28 weeks' gestation as previous guidelines have suggested. 22 If Hb levels cannot be measured for all pregnant patients, patients who at least should be considered for measurement of their Hb levels are those with some of the risk factors identified in this study such as women with cardiovascular disease undergoing planned C/S and women induced at early gestational ages. Women can also be considered for point-of-care testing of the Hb level for emergent procedures. Additionally, women with invasive placentation benefit from a targeted patient blood management program as they may be identified early in pregnancy and can be offered interventions such as iron supplementation, use of antifibrinolytics, and RBC saver to reduce the potential need for allogeneic RBCT. The results of this study identify a need for blood conserving measures for all obstetric patients. Although PPH and C/S are recognized risk factors for RBCT, 13, 22 and may not be predictable antenatally, the higher frequency of RBCT particularly for PPH found in this study (6-10%), higher than previously reported, 23-25 supports a universal approach for blood conservation.
If patient blood management is not feasible for all patients, risk stratification of the obstetric population based on the risk factors identified in the current study may be of use to identify women who stand to benefit the most from targeted management. For example, characteristics such as the presence of antepartum hemorrhage, cardiovascular disease, hemoglobinopathies, and/or invasive placentation may be used to develop risk scores to determine patients who have the greatest need for blood management strategies.
A low Hb concentration at delivery was found to be associated with RBCT for women undergoing C/S and SVD. The size of the sample for IVD may have been too 3, 26 Although the indication for RBCT cannot be definitely determined from a study using administrative databases, the findings suggest that by identifying and treating anemia antepartum, the exposure to RBCT may be reduced.
The increasing trend in the use of RBCT for patients undergoing C/S is unexpected. This trend was not associated with increasing maternal age as age did not result in a predisposition to RBCT. The increase may have been due to the high risk patient population who has C/ S at the Ottawa hospital but needs to be further explored. Nonetheless, more than 70% of procedures were elective C/S and thus there is an opportunity to further decrease exposure at delivery for planned procedures by considering routine use of antifibrinolytics or RBC salvage. Several randomized controlled trials have included patients receiving tranexamic acid prophylactically for C/S and have suggested that tranexamic acid is useful to reduce blood loss and RBCT. 27 RBC salvage is also an option as its use in obstetrics has not been associated with increased risk of alloimmunization or amniotic fluid embolism. 28 The limitations of administrative database analyses must be acknowledged. Indications for RBCT were not known. Rather, factors known to be associated with increased risk of bleeding and thus potentially associated with RBCT were included in the model. In addition, there were a considerable proportion of patients undergoing SVD for whom Hb levels were not available. Hb levels for uncomplicated pregnancies and deliveries are not typically determined as part of routine standard practice and so only those mothers receiving RBCT may have been more likely to have had their Hb levels determined for SVD. This was a single-center study and thus may have limited generalizability; however, the large sample size improves the validity of the results. In addition, the C/S rate for our cohort was 31.6%, which is consistent with other hospital centers in Canada. 29 Finally, the use of ICD-10 codes may not correlate with abstraction of medical records. Nonetheless most of the ICD-9 codes (that were revised to ICD-10 codes) used in this study were previously validated and we elected to only use ICD codes with a positive predictive value more than 70%. 18 In summary, we have identified that risk factors for RBCT differ according to mode of delivery so that future risk scores for RBCT can be developed according to the mode of delivery if possible. Hb concentrations measured antenatally can identify women with anemia so that correction with iron supplements can reduce the risk of anemia at delivery particularly for women who require induction at early gestational ages. Other options include the use of antifibrinolytic agents and RBC salvage. Ultimately, the aim is to decrease unnecessary RBCT exposure in obstetric patients to reduce both maternal and fetal morbidity.
